IFNB1 and myeloid sarcoma: For example, IFNβ treatment of MS patients can induce IL-10 production by myeloid cells, but treatment can also suppress production of granulocyte-macrophage colony-stimulating factor (GM-CSF), IFNγ, and TNF by effector T cells (334–340).